The Lambert Initiative has announced plans to investigate Avecho's low-dose CBD product in two additional clinical trials scheduled for later this year.
Researchers will focus on new indications not previously linked to CBD, using the company's low-dose soft-gel capsules as the basis for the studies.
The specific indications have not been made public, but they arose from pre-clinical and early-stage research carried out by Lambert.
Lambert academic director Iain McGregor said: "We have early evidence supporting the use of CBD in a number of new clinical indications and intend to examine these further in human clinical trials.
"We have been impressed by both the products and the quality of the science emerging from Avecho."
The new trials build on an ongoing partnership between the two organisations. The previous year, Lambert ran a phase II clinical trial examining a topical CBD product — developed using Avecho's TPM drug-delivery system — targeting osteoarthritis affecting the fingers and hands.
A larger topical trial is being planned for 2023, alongside a separate study involving cannabigerol (CBG).
Although Avecho's primary focus remains its upcoming phase III clinical trial for insomnia, chief executive Dr Paul Gavin said broadening the applications of its CBD medicine has always been part of the company's vision.
"The Lambert Initiative are Australia's foremost experts in cannabinoid research and we have learnt much about the clinical potential of cannabinoids through our interactions," he said.
"Their decision to use Avecho's CBD product in their own studies is testament to the clinical relevance of the work we've conducted over the last three years on product development."
Avecho's phase III clinical trial, which will form the basis of its over-the-counter TGA registration dossier, is set to span 10 sites and enrol 540 participants.
